Quality-of-life assessment after hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (taxol) in inoperable and/or unresectable head and neck squamous cell carcinoma

May Abdel-Wahab, Andre Abitbol, Alan Lewin, Michael Troner, Kara Hamilton, Arnold Markoe

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Purpose: To determine quality of life (QOL) after hyperfractionated radiation and chemotherapy. Materials and Methods: Functional Assessment of Cancer Therapy (FACT) and the Functional Assessment of Cancer Therapy-Head and Neck (FACT H-N) questionnaires were administered to protocol patients at baseline study entry, during and at the completion of therapy, and during subsequent follow-up. Results: Twenty-four patients completed baseline QOL questionnaires. Six subsequent assessments were given to patients who were available for follow-up. Social/family well-being and relationship with doctor subscores were not significantly different from baseline. Emotional well-being was not different from baseline initially, but actually showed a significant increase 6 months after completion of radiation, seen on assessments 5 and 6 (P < 0.01). Physical and functional well-being subscores, total FACT-G score, head and neck subscores, and total FACT H-N score all showed initial decreases during, at the completion of radiation, or, in some subscores, up to 3 months postradiation. However, all these scores recovered to baseline levels. These scores subsequently showed a significant increase after 6 months to 1 year in all but the physical well-being and head and neck subscores, which remained at baseline. Conclusion: QOL scores returned to baseline levels or increased at 6 to 12 months postradiation in long-term survivors who completed QOL questionnaires.

Original languageEnglish
Pages (from-to)359-366
Number of pages8
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume28
Issue number4
DOIs
StatePublished - Aug 1 2005

Fingerprint

Paclitaxel
Fluorouracil
Radiotherapy
Quality of Life
Radiation
Neck
Head
Therapeutics
Neoplasms
Head and Neck Neoplasms
Survivors
TP protocol
Carcinoma, squamous cell of head and neck
Drug Therapy
Surveys and Questionnaires

Keywords

  • Head and neck cancer
  • Hyperfractionated radiation therapy
  • Quality of life

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{cb0e626181484e7c9211cec80b0d8a0b,
title = "Quality-of-life assessment after hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (taxol) in inoperable and/or unresectable head and neck squamous cell carcinoma",
abstract = "Purpose: To determine quality of life (QOL) after hyperfractionated radiation and chemotherapy. Materials and Methods: Functional Assessment of Cancer Therapy (FACT) and the Functional Assessment of Cancer Therapy-Head and Neck (FACT H-N) questionnaires were administered to protocol patients at baseline study entry, during and at the completion of therapy, and during subsequent follow-up. Results: Twenty-four patients completed baseline QOL questionnaires. Six subsequent assessments were given to patients who were available for follow-up. Social/family well-being and relationship with doctor subscores were not significantly different from baseline. Emotional well-being was not different from baseline initially, but actually showed a significant increase 6 months after completion of radiation, seen on assessments 5 and 6 (P < 0.01). Physical and functional well-being subscores, total FACT-G score, head and neck subscores, and total FACT H-N score all showed initial decreases during, at the completion of radiation, or, in some subscores, up to 3 months postradiation. However, all these scores recovered to baseline levels. These scores subsequently showed a significant increase after 6 months to 1 year in all but the physical well-being and head and neck subscores, which remained at baseline. Conclusion: QOL scores returned to baseline levels or increased at 6 to 12 months postradiation in long-term survivors who completed QOL questionnaires.",
keywords = "Head and neck cancer, Hyperfractionated radiation therapy, Quality of life",
author = "May Abdel-Wahab and Andre Abitbol and Alan Lewin and Michael Troner and Kara Hamilton and Arnold Markoe",
year = "2005",
month = "8",
day = "1",
doi = "10.1097/01.coc.0000158837.47450.81",
language = "English",
volume = "28",
pages = "359--366",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Quality-of-life assessment after hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (taxol) in inoperable and/or unresectable head and neck squamous cell carcinoma

AU - Abdel-Wahab, May

AU - Abitbol, Andre

AU - Lewin, Alan

AU - Troner, Michael

AU - Hamilton, Kara

AU - Markoe, Arnold

PY - 2005/8/1

Y1 - 2005/8/1

N2 - Purpose: To determine quality of life (QOL) after hyperfractionated radiation and chemotherapy. Materials and Methods: Functional Assessment of Cancer Therapy (FACT) and the Functional Assessment of Cancer Therapy-Head and Neck (FACT H-N) questionnaires were administered to protocol patients at baseline study entry, during and at the completion of therapy, and during subsequent follow-up. Results: Twenty-four patients completed baseline QOL questionnaires. Six subsequent assessments were given to patients who were available for follow-up. Social/family well-being and relationship with doctor subscores were not significantly different from baseline. Emotional well-being was not different from baseline initially, but actually showed a significant increase 6 months after completion of radiation, seen on assessments 5 and 6 (P < 0.01). Physical and functional well-being subscores, total FACT-G score, head and neck subscores, and total FACT H-N score all showed initial decreases during, at the completion of radiation, or, in some subscores, up to 3 months postradiation. However, all these scores recovered to baseline levels. These scores subsequently showed a significant increase after 6 months to 1 year in all but the physical well-being and head and neck subscores, which remained at baseline. Conclusion: QOL scores returned to baseline levels or increased at 6 to 12 months postradiation in long-term survivors who completed QOL questionnaires.

AB - Purpose: To determine quality of life (QOL) after hyperfractionated radiation and chemotherapy. Materials and Methods: Functional Assessment of Cancer Therapy (FACT) and the Functional Assessment of Cancer Therapy-Head and Neck (FACT H-N) questionnaires were administered to protocol patients at baseline study entry, during and at the completion of therapy, and during subsequent follow-up. Results: Twenty-four patients completed baseline QOL questionnaires. Six subsequent assessments were given to patients who were available for follow-up. Social/family well-being and relationship with doctor subscores were not significantly different from baseline. Emotional well-being was not different from baseline initially, but actually showed a significant increase 6 months after completion of radiation, seen on assessments 5 and 6 (P < 0.01). Physical and functional well-being subscores, total FACT-G score, head and neck subscores, and total FACT H-N score all showed initial decreases during, at the completion of radiation, or, in some subscores, up to 3 months postradiation. However, all these scores recovered to baseline levels. These scores subsequently showed a significant increase after 6 months to 1 year in all but the physical well-being and head and neck subscores, which remained at baseline. Conclusion: QOL scores returned to baseline levels or increased at 6 to 12 months postradiation in long-term survivors who completed QOL questionnaires.

KW - Head and neck cancer

KW - Hyperfractionated radiation therapy

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=23244449239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23244449239&partnerID=8YFLogxK

U2 - 10.1097/01.coc.0000158837.47450.81

DO - 10.1097/01.coc.0000158837.47450.81

M3 - Article

C2 - 16062077

AN - SCOPUS:23244449239

VL - 28

SP - 359

EP - 366

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 4

ER -